TheraVet マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Gaetan Terrasse

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Gaetan Terrasse

no data

在職期間

Gaetan Terrasse is Managing Director of TheraVet SA from November 15, 2024.

取締役

名称	ポジション	在職期間	報酬	所有権
Simon Wheeler	Independent Director	2.9yrs	データなし	データなし
Nesya Goris	Independent Director	2.9yrs	データなし	データなし
Olivier Gauthier	Member of Scientific Advisory Board	no data	データなし	データなし
Marc Balligand	Chairman of Scientific Advisory Board	no data	データなし	データなし
Guillaume Ragetly	Member of Scientific Advisory Board	no data	データなし	データなし
Ulrich Rytz	Member of Scientific Advisory Board	no data	データなし	データなし
Emmanuel Huynh	Chairman	no data	データなし	データなし

2.9yrs

平均在職期間

経験豊富なボード: ALVETの取締役会は経験豊富ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

TheraVet マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

EGEIRO Pharma Announces Management Changes

TheraVet SA, Annual General Meeting, Jun 05, 2025

TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

EGEIRO Pharma Announces Management Changes

New minor risk - Shareholder dilution

First half 2024 earnings released: €0.26 loss per share (vs €0.28 loss in 1H 2023)

New major risk - Revenue size

TheraVet SA, Annual General Meeting, Jun 05, 2025

TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study

New major risk - Financial position

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

TheraVet SA Announces the Launch of BIOCERA-VET Equine

TheraVet SA Announces Commercial Launch of Biocera-VET in Germany

TheraVet Announces Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy

TheraVet SA Announces Launch of Biocera-Vet Canine Osteosarcoma Study Conducted by the University of Florida

TheraVet SA announced that it expects to receive €1 million in funding

TheraVet SA announced that it expects to receive €1 million in funding

TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer

New major risk - Share price stability

TheraVet SA Announces Patient Recruitment Phase Successfully Completed in Biocera-Vet Fracture Revision Surgery Study in Toy Dogs

First half 2023 earnings released

TheraVet SA to Report First Half, 2024 Results on Sep 12, 2024

TheraVet SA Announces the Commercial Launch of A Local and Sustained Antibiotic Releasing Bone Substitute

Full year 2022 earnings released

Less than half of directors are independent

TheraVet SA to Report First Half, 2023 Results on Sep 06, 2023

First half 2022 earnings released: EPS: €0 (vs €0.24 loss in 1H 2021)

TheraVet SA to Report First Half, 2022 Results on Sep 09, 2022

TheraVet Announces the Commercial Launch of its BIOCERA-VET Product Line in the United States of America

TheraVet SA Announces the Commercial Launch of the Bone Substitutes in the Veterinary Market

Less than half of directors are independent

TheraVet SA to Report Fiscal Year 2021 Results on Apr 06, 2022

TheraVet SA Broadens Bone Substitutes Portfolio with an Innovative Line of Biological Bone Grafts

TheraVet SA presents Positive Results of Biocera-Vet-Bone Surgery Presented at the Annual Conference of the US Veterinary Orthopedic Society and Confirmed on a Larger Patients Cohort

Theravet Announces Commercial Launch of Biocera-Vet® for Canine Osteosarcoma in Belgium, France and the Netherlands

TheraVet Announces the Launch of the Pivotal European Multicentric Clinical Study of VISCO-VET in Canine Osteoarthritis

TheraVet Announces Positive Safety and Efficacy Results for VISCO-VET in Canine Osteoarthritis

TheraVet Extends the Use of BIOCERA-VET to a New Curative Approach of Osteosarcoma in Dogs Through an Innovative and Multidisciplinary Management

CEO（最高経営責任者

在職期間

取締役

平均在職期間

マネジメント基準チェック /04